Hem › Sklerodermi › Illinois
Kliniska studier för Sklerodermi i Illinois
11 studier för Sklerodermi söker deltagare vid platser i Illinois.
Städer i Illinois
Officiell studietext (engelska)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Northwestern University, Chicago
- The University of Chicago Medical Center, Chicago
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- University of Illinois Health Outpatient Care Center, Chicago
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2026 · NCT06655155A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
RekryterarFas 1
Ålder 18 till 74 · Alla kön · Uppdaterad 10 sep. 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Chicago
RekryterarFas 2/3
Ålder 18 och äldre · Alla kön · Uppdaterad 8 sep. 2026 · NCT05878717A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
RekryterarFas 1
Ålder 18 till 70 · Alla kön · Uppdaterad 28 aug. 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- The University of Chicago Medical Center (UCMC), Chicago
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 18 aug. 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
RekryterarFas 2/3
Ålder 18 till 75 · Alla kön · Uppdaterad 17 aug. 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Chicago
RekryterarFas 1/2
Ålder 18 till 75 · Alla kön · Uppdaterad 7 aug. 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Willowbrook, Willowbrook
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 31 juli 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chicago
RekryterarFas 1
Ålder 18 till 75 · Alla kön · Uppdaterad 28 juli 2026 · NCT07295847Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 7 maj 2025 · NCT05892614Från ClinicalTrials.gov, data hämtad 2 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.